Search Results - "Christos EMMANOUILIDES"

Nonlinearity in high-frequency stock returns: Evidence from the Athens Stock Exchange by Anagnostidis, Panagiotis, Emmanouilides, Christos J.

“…This study investigates empirically the presence of nonlinearities in the Athens Composite Share Price Index high-frequency returns. A preliminary analysis…”
Get full text

Reorganisation of Oncologic Care in Greece: A Proposal by Emmanouilides, Christos

“…Cancer is becoming a major public health issue as patients enjoy longer survivals than ever before due to the introduction innovative but expensive drugs in…”
Get full text

Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma by LEVY, Ronald, GANJOO, Kristen N, NICHOLS, Craig, EMMANOUILIDES, Christos E, TIMMERMAN, John M, GREGORY, Stephanie A, LINK, Brian K, INWARDS, David J, FREEDMAN, Arnold S, MATOUS, Jeffrey V, ROBERTSON, Michael J, KUNKEL, Lori A, LEONARD, John P, INGOLIA, Diane E, GENTLES, Andrew J, CHIH LONG LIU, TIBSHIRANI, Robert, ALIZADEH, Ash A, DENNEY, Dan W, VOSE, Julie M, FLINN, Ian W, AMBINDER, Richard F, CONNORS, Joseph M, BERINSTEIN, Neil L, BELCH, Andrew R, BARTLETT, Nancy L

“…Idiotypes (Ids), the unique portions of tumor immunoglobulins, can serve as targets for passive and active immunotherapies for lymphoma. We performed a…”
Get full text

Testing for the LOP under nonlinearity: an application to four major EU pork markets by Emmanouilides, Christos J, Fousekis, Panos

“…This article develops an econometric procedure to test the validity of the Law of One Price (LOP) under nonlinearity and to distinguish between its strong and…”
Get full text

Vertical price dependence structures: copula-based evidence from the beef supply chain in the USA by Emmanouilides, C. J., Fousekis, P.

“…The objective of this paper is to assess the degree and the structure of price dependence along the beef supply chain in the USA. This is pursued using the…”
Get full text

Palifermin for Oral Mucositis after Intensive Therapy for Hematologic Cancers by Spielberger, Ricardo, Stiff, Patrick, Bensinger, William, Gentile, Teresa, Weisdorf, Daniel, Kewalramani, Tarun, Shea, Thomas, Yanovich, Saul, Hansen, Keith, Noga, Stephen, McCarty, John, LeMaistre, C. Frederick, Sung, Eric C, Blazar, Bruce R, Elhardt, Dieter, Chen, Mon-Gy, Emmanouilides, Christos

“…Oral mucositis can be a debilitating and dangerous adverse effect of the chemoradiation used to prepare patients for bone marrow transplantation. Palifermin, a…”
Get full text

Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Patients Treated With Ibritumomab Tiuxetan Radioimmunotherapy by CZUCZMAN, Myron S, EMMANOUILIDES, Christos, DARIF, Mohamed, WITZIG, Thomas E, GORDON, Leo I, REVELL, Stephen, VO, Katie, MOLINA, Arturo

“…To investigate the incidence of treatment-related myelodysplastic syndrome (t-MDS) and treatment-related acute myelogenous leukemia (t-AML) after treatment…”
Get full text

Biosimilars: Hope and concern by Emmanouilides, Christos E, Karampola, Maria I, Beredima, Maria

“…As patents of the first introduced biologic therapeutics in oncology have begun to expire, competing pharmaceutical companies are allowed to produce and market…”
Get full text

Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma by WITZIG, Thomas E, GORDON, Leo I, GRILLO-LOPEZ, Antonio J, MULTANI, Pratik, WHITE, Christine A, CABANILLAS, Fernando, CZUCZMAN, Myron S, EMMANOUILIDES, Christos, JOYCE, Robin, POHLMAN, Brad L, BARTLETT, Nancy L, WISEMAN, Gregory A, PADRE, Norman

“…Radioimmunotherapy combines biologic and radiolytic mechanisms to target and destroy tumor cells, thus offering a needed therapeutic alternative for refractory…”
Get full text

Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma by WITZIG, Thomas E, FLINN, Ian W, WHITE, Christine A, GORDON, Leo I, EMMANOUILIDES, Christos, CZUCZMAN, Myron S, SALEH, Mansoor N, CRIPE, Larry, WISEMAN, Gregory, OLEJNIK, Teresa, MULTANI, Pratik S

“…Rituximab is commonly used as a single agent or in combination therapy for non-Hodgkin's lymphoma (NHL). Ibritumomab tiuxetan radioimmunotherapy targets the…”
Get full text

Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: Pivotal role of p38 MAPK in drug resistance by VEGA, Mario I, HUERTA-YEPAZ, Sara, GARBAN, Hermes, JAZIREHI, Ali, EMMANOUILIDES, Christos, BONAVIDA, Benjamin

“…We have recently reported that Rituximab (anti-CD20) sensitizes drug-resistant 2F7 and 10C9 B Non-Hodgkin's lymphoma (NHL) cell lines to the apoptotic effects…”
Get full text

Palifermin Reduces Patient-Reported Mouth and Throat Soreness and Improves Patient Functioning in the Hematopoietic Stem-Cell Transplantation Setting by STIFF, Patrick J, EMMANOUILIDES, Christos, BENSINGER, William I, GENTILE, Teresa, BLAZAR, Bruce, SHEA, Thomas C, LU, John, ISITT, John, CESANO, Alessandra, SPIELBERGER, Ricardo

“…To describe patient-reported outcomes of mouth and throat soreness (MTS) and related sequelae on daily activities from a phase III study of palifermin in the…”
Get full text

Polymorphisms in FcγRIIIA (CD16) Receptor Expression Are Associated With Clinical Response to Rituximab in Waldenström’s Macroglobulinemia by TREON, Steven P, HANSEN, Mark, MALONEY, David G, FOX, Edward A, BRANAGAN, Andrew R, VERSELIS, Sigitas, EMMANOUILIDES, Christos, KIMBY, Eva, FRANKEL, Stanley R, TOUROUTOGLOU, Nikolaos, TURNBULL, Barry, ANDERSON, Kenneth C

“…Purpose Rituximab is an important therapeutic for Waldenström’s macroglobulinemia (WM). Polymorphisms in FcγRIIIA (CD16) receptor expression modulate human…”
Get full text

Inhibition of Interleukin 10 by Rituximab Results in Down-Regulation of Bcl-2 and Sensitization of B-cell Non-Hodgkin’s Lymphoma to Apoptosis by ALAS, Steve, EMMANOUILIDES, Christos, BONAVIDA, Benjamin

“…Treatment of patients with non-Hodgkin’s lymphoma (NHL) is frequently hampered by development of chemoresistance. Rituximab is a chimeric mouse antihuman CD20…”
Get full text

Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study by Gordon, Leo I., Molina, Arturo, Witzig, Thomas, Emmanouilides, Christos, Raubtischek, Andrew, Darif, Mohamed, Schilder, Russell J., Wiseman, Greg, White, Christine A.

“…We previously demonstrated that yttrium-90 (Y-90) ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) was safe and effective for relapsed or refractory…”
Get full text

Assessing the Validity of the LOP in the EU Broiler Markets by Emmanouilides, Christos J., Fousekis, Panos

“…ABSTRACT The objective of this article is to assess the validity of the Law of One Price (LOP) in five major EU broiler markets. This has been pursued using…”
Get full text

Safety of Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy for Relapsed Low-Grade, Follicular, or Transformed Non-Hodgkin’s Lymphoma by WITZIG, Thomas E, WHITE, Christine A, GORDON, Leo I, WISEMAN, Gregory A, EMMANOUILIDES, Christos, MURRAY, James L, LISTER, John, MULTANI, Pratik S

“…Radioimmunotherapy (RIT) with yttrium-90 ((90)Y)-labeled anti-CD20 antibody ((90)Y ibritumomab tiuxetan; Zevalin, IDEC Pharmaceuticals Corporation, San Diego,…”
Get full text

Front-Line Bevacizumab plus Chemotherapy with or without Maintenance Therapy for Metastatic Breast Cancer: An Observational Study by the Hellenic Oncology Research Group by Kokkali, Stefania, Saloustros, Emmanouil, Stefanou, Dimitra, Makrantonakis, Paris, Kentepozidis, Nikolaos, Boukovinas, Ioannis, Xenidis, Nikolaos, Katsaounis, Panagiotis, Ardavanis, Alexandros, Ziras, Nikolaos, Christopoulou, Athina, Rigas, George, Kalbakis, Kostas, Vardakis, Nikolaos, Emmanouilides, Christos, Athanasiadis, Ilias, Anagnostopoulos, Athanassios, Hatzidaki, Dora, Prinarakis, Efthimios, Simopoulou, Foteini, Kotsakis, Athanasios, Georgoulias, Vassilis

“…Front-line bevacizumab (BEV) in combination with taxanes offers benefit in progression-free survival (PFS) in metastatic breast cancer (mBC). The medical…”
Get full text

Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non–Hodgkin's Lymphoma by LEONARD, John P, LINK, Brian K, KRIEG, Arthur M, WEINER, George J, EMMANOUILIDES, Christos, GREGORY, Stephanie A, WEISDORF, Daniel, ANDREY, Jeffrey, HAINSWORTH, John, SPARANO, Joseph A, TSAI, Donald E, HORNING, Sandra

“…Purpose: PF-3512676 (formerly CpG 7909) is a novel Toll-like receptor 9–activating oligonucleotide with single-agent antitumor activity that augments…”
Get full text

Radioimmunotherapy for Non-Hodgkin Lymphoma : Historical Perspective and Current Status by Emmanouilides, Christos

“…Radioimmunotherapy (RIT) treatment for lymphoma is a novel targeted therapeutic approach. Several years of development of radioimmunotherapeutic compounds came…”
Get full text